tiprankstipranks
Trending News
More News >

Abbisko Therapeutics Advances Achondroplasia Study with First Patient Enrollment

Story Highlights
Abbisko Therapeutics Advances Achondroplasia Study with First Patient Enrollment

Don’t Miss TipRanks’ Half-Year Sale

Abbisko Cayman Limited ( (HK:2256) ) just unveiled an update.

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient enrollment for an observational study aimed at treating children with Achondroplasia (ACH). This study will gather baseline data for ABSK061, a selective small molecule inhibitor of FGFR2/3, which could potentially offer a new treatment option for ACH, a rare disorder with no specific medications currently available in China. The successful enrollment marks a significant step in Abbisko’s efforts to address this unmet medical need and could enhance its positioning in the biopharmaceutical industry.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company. It is dedicated to discovering and developing innovative medicines to address unmet medical needs in China and globally, with a focus on precision oncology and immuno-oncology.

Average Trading Volume: 5,596,496

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.06B

For an in-depth examination of 2256 stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1